Saturday, July 15, 2023 10:42:08 AM
Here’s what I think is the global healthcare business model that slowed DCVax but still allows L to ultimately step forward. (FDA/SEC are captive to special interests.)
BP products will be disrupted by DCVax, cancer surgery economy would be disrupted by DCVax-Direct, NVCR will be decimated by L and/or direct, high cost clean rooms and excessive employee count will be unnecessary with Eden and its offspring.
L is like a godsend to make the transition to better patient treatment more palatable to all the above self-interested groups. It combines with current lucrative BP products, it still requires surgery or at least large biopsy material, it still requires clean room production and associated workers for now.
L is essentially a decompression chamber so that all the above interests don’t get the Benz as medical care surfaces toward a better and more humane approach. Direct will eventually move forward, imho, but the above forces trying to hold it off will need time to come to terms with their respective sugar daddies’ mortality.
BP products will be disrupted by DCVax, cancer surgery economy would be disrupted by DCVax-Direct, NVCR will be decimated by L and/or direct, high cost clean rooms and excessive employee count will be unnecessary with Eden and its offspring.
L is like a godsend to make the transition to better patient treatment more palatable to all the above self-interested groups. It combines with current lucrative BP products, it still requires surgery or at least large biopsy material, it still requires clean room production and associated workers for now.
L is essentially a decompression chamber so that all the above interests don’t get the Benz as medical care surfaces toward a better and more humane approach. Direct will eventually move forward, imho, but the above forces trying to hold it off will need time to come to terms with their respective sugar daddies’ mortality.
Recent NWBO News
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
